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Introduction
Satellite cells are self-renewing muscle stem cells, which me-
diate the growth and repair of skeletal muscle (Zammit et al., 
2006). When the muscle is damaged, these cells leave their 
state of quiescence, proliferate at length to generate colonies 
of myoblasts, and then differentiate to form multinucleated 
myotubes (Zammit et al., 2006). The myogenic factor that is 
mainly involved in controlling the progression of these myo-
blasts into the differentiation state is MyoD (Le Grand and 
Rudnicki, 2007). This protein, which preferentially binds to a 
DNA consensus site (CANNTG) called an E-box, has been 
shown in both myogenic (C2C12) and nonmyogenic cell lines 
to be highly important in controlling the transcription of dif-
ferentiation-specific genes (Berkes and Tapscott, 2005). This 
function correlates in part to the ability of MyoD to recruit 
histone acetyltransferases (e.g., PCAF and p300) and SWI/
SNF  chromatin-remodeling  complexes  to  the  promoters  of 
these genes to affect specific changes in chromatin structure 
(Mal and Harter, 2003; Berkes et al., 2004). Another myogenic 
factor that is highly related to MyoD in both amino acid   
sequence and affinity to E-box sites is Myf5 (Tapscott, 2005). 
Mice that are null for either MyoD or Myf5 are viable, and 
therefore, it is widely believed that these two proteins can 
functionally substitute for one another during embryonic devel-
opment (Le Grand and Rudnicki, 2007). However, this com-
pensation may not be as efficient in the regeneration of muscle 
because  cultures  of  MyoD
/  myoblasts,  which  apparently 
have 5–10 times more Myf5 protein, are dramatically delayed 
in their transition to a differentiated state (Sabourin et al., 1999; 
Yablonka-Reuveni et al., 1999). Moreover, these myoblasts 
also appear to be limited in their ability to expand in population 
when compared with wild type (Montarras et al., 2000), and 
this may reflect the fact that Myf5 is less effective than MyoD 
in regulating the same set of growth-phase genes (Montarras 
et al., 2000; Ishibashi et al., 2005).
There is evidence to suggest that MyoD may also be 
playing a role in helping satellite cells to expand in popu-
lation  upon  leaving  quiescence.  For  example,  MyoD  has 
been  shown  to  be  expressed  within  3  h  after  the  satellite 
cells have been activated (Jones et al., 2005). In addition, 
ChIP (chromatin immunoprecipitation)-on-chip analysis has 
shown that MyoD can target genes other than those involved 
in the myogenic program, and in this group were Cdc6 and 
MCM2. These two genes are primarily involved in making 
chromatin operational for DNA replication, a function which 
is not only essential for the proliferation of cells but also 
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yoD is a transcriptional factor that is required 
for the differentiation of muscle stem cells (satel-
lite cells). In this study, we describe a previously 
unknown function for MyoD in regulating a gene (Cdc6) 
that is vital to endowing chromatin with the capability of 
replicating  DNA.  In  C2C12  and  primary  mouse  myo-
blasts, we show that MyoD can occupy an E-box within 
the promoter of Cdc6 and that this association, along with 
E2F3a, is required for its activity. MyoD and Cdc6 are 
both expressed after quiescent C2C12 myoblasts or satel-
lite cells in association with myofibers are stimulated for 
growth, but MyoD appears at least 2–3 h earlier than 
Cdc6. Finally, knockdown of MyoD impairs the ability of 
C2C12 cells to express Cdc6 after leaving quiescence, 
and as a result, they cannot fully progress into S phase. 
Our results define a mechanism by which MyoD helps 
myogenic satellite cells to enter into the first round of DNA 
replication after transitioning out of quiescence.
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Results
Analysis of promoters for potential  
E-box sites
To identify potential MyoD-binding sites in the regulatory   
regions of genes that have been identified in inducing DNA repli-
cation, we used TRANSFAC (version 7.0, cut off 85), a data-
base which models factor-site interactions on the sequences of 
DNA (Matys et al., 2006). With this computer-assisted analysis, 
we were able to identify within the promoters of Cdc6 and 
MCM2 and -7 a consensus DNA site known as an E-box for the 
binding of MyoD (Fig. S1 A and not depicted). The Cdc6 pro-
moter, the one we chose to focus on, was found to contain two 
of these sites, with one (E1) being in close proximity to the 
transcriptional start site (+1) and the other (E2) much further 
upstream (Fig. 1 A). The position of the start site within this 
promoter corresponds to the 5 terminus of an mRNA (Materials 
and methods) that is predicted to encode a protein of 62 kD, 
and in fact, a protein matching this size can be observed in   
extracts of proliferating C2C12 myoblasts, as judged by Western 
blot analysis (Fig. S1 B). The regulatory region of Cdc6 also 
contains two potential E2F-binding sites close to the transcription 
start site, and interestingly, one of them is located 10 bp upstream 
from the E1 E-box (Fig. 1 A). The arrangement of these two 
E2F elements is quite similar to that found in the human Cdc6 
promoter (Williams et al., 1997), and it has been reported that 
the one nearest to the start site is mainly involved in stimulating 
its activity in nonmuscle cells (Schlisio et al., 2002).
Both MyoD and E2F can occupy the 
promoter of Cdc6 in myoblasts
We used the myogenic cell line C2C12 and mouse primary 
myoblasts to determine by ChIP whether any of the E-boxes 
within the endogenous Cdc6 promoter were capable of associating 
for cells emerging from quiescence (Blais et al., 2005; for 
review see Machida et al., 2005). MCM2 is a member of the 
MCM family of proteins (MCM2–7), and as a complex, these 
proteins along with Cdc6 and at least seven other proteins   
assemble at origins of DNA replication to form what is called 
a prereplicative complex. Studies have shown that Cdc6 is a 
key participant in this process because it essentially loads 
the MCM proteins onto the origins (for review see Machida 
et al., 2005). Because prereplicative complexes are largely 
involved in unwinding the DNA and initiating the process 
of replication, it is perhaps not surprising to find that the 
genes of many of its members, including Cdc6 and MCM2, 
have become temporarily silent in quiescent cells (Yan et al., 
1998; Ren et al., 2002; Ghosh and Harter, 2003). Although 
this scenario has yet to be demonstrated in satellite cells, it 
is most likely that analogous mechanisms would occur, and 
if so, it is possible that MyoD could be involved in inducing 
transcription from either Cdc6 or MCM2 in these cells after   
leaving quiescence.
In this study, we have used mouse primary myoblasts (wild 
type or MyoD
/), isolated myofibers with associated satel-
lite cells, and the satellite-derived C2C12 cell line to investi-
gate whether MyoD can possibly regulate genes that are an 
integral part of the replication system. Through biochemistry   
and RNAi experiments, we have uncovered a mechanism that 
involves MyoD in initiating the expression of Cdc6 in growth-
stimulated quiescent myoblasts and shown that this induction 
is essential for effectively moving these cells into S phase. 
Furthermore, the importance of MyoD’s activity in this context 
is underscored by Myf5’s ability to perform this function in the 
absence of MyoD, although with less efficiency. Thus, our results 
have established a new and unexpected role for MyoD, and by 
all accounts, one that may be important to satellite cells as they 
transition out of quiescence.
Figure 1.  MyoD occupies the Cdc6 promoter 
in myoblasts. (A) Schematic of the Cdc6 pro-
moter. Closed ovals (E1 and E2) and squares 
identify the putative MyoD (E-boxes) and E2F 
sites within the promoter, respectively. The in-
verted arrows represent the primers used in the 
PCR amplification reactions. The transcription 
start site is depicted with an arrow. (B) Cross-
linked  chromatin  from  C2C12  myoblasts  or 
primary mouse myoblasts cultured in GM was 
immunoprecipitated in parallel with anti-MyoD 
antibody (Ab) and then analyzed by semiquan-
titative PCR using primers surrounding the E1 
and E2 sites in the Cdc6 promoter. A control 
reaction with the use of normal rabbit IgG (NR 
IgG) is shown along with input DNA (0.05%), 
which was amplified by the same set of prim-
ers. Black lines indicate that intervening lanes 
have been spliced out. (C) ChIP experiments 
were performed in parallel on chromatin from 
C2C12 myoblasts before and after differentia-
tion using normal rabbit IgG or an antibody 
specific  for  MyoD.  Precipitated  DNA  was 
then analyzed by PCR using the E1 primers, 
and afterward, the bands were quantified by 
ImageJ (version 1.36b; National Institutes of 
Health). Controls for PCR included the use of normal rabbit IgG and the titration of input DNA to ensure all amplifications were within the linear range 
(Fig. S1 D). (D) Values in the histogram represent the ratio of chromatin-bound MyoD to input genomic DNA and are the mean of three independent 
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shown in the human Cdc6 promoter (Schlisio et al., 2002). We 
also observed in this analysis that E2F1 was noticeably absent 
from the Cdc6 promoter (Fig. 2 A), and again, this result is 
consistent with what has been previous reported for the human 
Cdc6 promoter (Takahashi et al., 2000; Ren et al., 2002; Schlisio 
et al., 2002). E2F3a has been reported to play an important role 
in controlling genes that are critical to the replication of DNA. 
In fact, the ability of cells to enter S phase after being released 
from a G1/S block becomes markedly diminished if E2F3a is 
purposely made inactive (Leone et al., 1998). Because of this 
and the fact that the cessation of DNA synthesis is concurrent 
with the differentiation of muscle cells, we examined by ChIP 
assays the relationship between E2F3a and the Cdc6 promoter 
after myoblasts were induced to differentiate. We found by 
temporal analysis that E2F3a could no longer be detected on 
the Cdc6 promoter after 24 h of differentiation (Fig. 2 B). 
Perhaps equally important is that this loss also corresponded to   
a linear increase in the association of E2F4 with this promoter 
(Fig. 2 C). This observation and the fact that E2F4 functions 
primarily as a repressor of transcription (Blais et al., 2005) 
may be one reason why the expression of Cdc6 is no longer 
seen in differentiated muscle cells, either by immunofluores-
cence or by RT-PCR analysis (Fig. 2 D). We note that Cdc6 is 
primarily  located  in  the  nucleus  of  proliferating  myoblasts, 
with some evidence of it in the cytoplasm (Fig. 2 D). This phe-
nomenon has also been observed by others (Petersen et al., 
1999;  Delmolino  et  al.,  2001)  presumably  because  Cdc6   
remains chromatin bound after S phase is initiated so that it   
can then participate in other cellular functions such as mitotic 
entry (Clay-Farrace et al., 2003).
with MyoD. After immunoprecipitating cross-linked DNA frag-
ments of 100–400 bp with antibodies specific for MyoD, we 
found that MyoD could associate with this promoter in both of 
these cellular environments but only near the E1 site (Fig. 1 B). 
The interaction of MyoD with this promoter was not the result 
of a promiscuous interaction because it was also able to occupy 
the  downstream  and  upstream  regulatory  regions  of  MCM2  
and -7, respectively (Fig. S1 C and not depicted; Juven-Gershon 
et al., 2008). ChIP assays in combination with kinetic experi-
ments were then used to determine whether MyoD remained 
bound to the Cdc6 promoter after the myoblasts were induced 
to differentiate. As shown in Fig. 1 (C and D), the interaction of 
MyoD with this promoter diminished over time as myoblasts 
underwent the process of differentiation. This result is signifi-
cant because it indicates a requirement for MyoD in regulating 
the expression of Cdc6 in satellite cells, but only while the cells 
are in a state of proliferation.
ChIP  experiments  were  also  performed  to  determine 
whether any member of the E2F family of transcription factors 
(E2F1–7) might be interacting with the Cdc6 promoter in pro-
liferating myoblasts. As shown in Fig. 2 A, E2F3a, an isoform 
mainly expressed in growing cells (Leone et al., 2000), was 
found to be the most predominant factor in association with 
this promoter, although a weak binding by E2F4 could also be 
observed. Note that the near absence of E2F4 from the Cdc6 
promoter was not the result of an antibody that had lost its 
specificity when used in a ChIP assay (Fig. 2 C). Although the 
site on the promoter to which E2F3a is binding has yet to be 
identified, it is possible that it may be the one closest to the 
transcriptional  start  site  (Fig.  1 A),  as  has  been  previously 
Figure 2.  E2F3a occupies the Cdc6 promoter in myoblasts, but 
it is replaced by E2F4 after differentiation. (A) ChIP of C2C12 
myoblasts  cultured  in  GM  with  antibodies  (Ab)  detecting   
E2F1, E2F3a, and E2F4. As a control, ChIP was also per-
formed in parallel with normal rabbit IgG (NR IgG). Purified 
DNA from enriched chromatin fragments was amplified by 
PCR with the E1 primers. (B and C) ChIP of C2C12 myoblasts 
cultured in DM at the indicated times using normal rabbit IgG 
and either anti-E2F3a or anti-E2F4, respectively. Precipitated 
DNA was analyzed for the presence of the Cdc6 promoter 
by PCR. (D) The occupation of the Cdc6 promoter by E2F4   
correlates with its silencing in differentiated myoblasts. Immuno-
fluorescent staining of C2C12 myoblasts cultured in GM or 
DM for 96 h was performed by using a Cdc6-specific anti-
body. Antibody staining is visualized as red. RT-PCR detection 
of Cdc6 transcripts in C2C12 myoblasts cultured in GM or in 
DM for 72 or 96 h. GAPDH expression is used as a loading 
control. White lines indicate that intervening lanes have been 
spliced out. Bars, 20 µm.JCB • VOLUME 188 • NUMBER 1 • 2010   42
activity of its promoter had increased substantially when com-
pared with its activity without Myf5 (Fig. S1 F). As expected, 
the activity of the mutant Cdc6 promoter (Cdc6-E1mut) was 
dramatically diminished after it was cotransfected into these 
cells with pCMV-Myf5 (Fig. S1 F). It would appear then that 
the proximal promoter region of Cdc6 is responsive to Myf5 
as well, and this may be significant in light of the observations 
described below (see Fig. 6).
To  further  investigate  the  relationship  between  MyoD 
and the Cdc6 promoter and, more importantly, to ensure that 
the aforementioned results were not associated with an over-
expressed MyoD, we introduced each of the reporter constructs 
into C2C12 myoblasts. As shown in Fig. 3 C, the transfected 
Cdc6-wt reporter responded to endogenous MyoD by showing a 
dramatic increase in its promoter activity (an 50-fold increase)   
relative to empty vector. However, the Cdc6-E1mut construct 
responded by showing at least a threefold reduction in its   
promoter activity when compared with that of the wild-type   
vector (Fig. 3 C), thereby lending further support to a role for the 
E1 site in controlling the Cdc6 promoter. To determine whether 
both the E2F and E1 sites were required for precise functioning 
of the Cdc6 promoter, we constructed two additional vectors in 
which the E2F-binding site (Cdc6-mut2) or both the E2F- and   
E1-binding sites (Cdc6-mut1/2) were altered by mutations   
(Fig. 3 C). Myoblasts were then separately transfected with each 
of these vectors. As shown in Fig. 3 C, the promoter activity of 
the Cdc6 reporter holding a mutation only in the E2F-binding 
site was significantly reduced when compared with that of wild 
type. What is more important, though, is that mutations in both 
The proximal promoter of Cdc6 is 
responsive to MyoD, Myf5, and E2F
To determine whether the E1 site was functionally important to 
the activity of the Cdc6 promoter, we first assessed the response 
of a reporter construct (Cdc6-wt) carrying the regulatory ele-
ments of Cdc6 in a cell line (C3H10T1/2) that does not express   
endogenous MyoD protein (Fig. 3 A). After this vector and a 
vector devoid of the Cdc6 elements were separately transfected 
into these cells, we found that the promoter activity of Cdc6-wt 
was enhanced at least sixfold when compared with the empty 
vector (Fig. 3 B). More importantly, though, this level of activ-
ity, which may be caused by an E2F (Fig. 2 A and Fig. S1 E), 
increased significantly in a dose-dependent manner after the 
Cdc6-wt vector was cotransfected with a vector expressing 
increasing amounts of MyoD (pCMV-MyoD; Fig. 3 B). To verify 
that this effect was truly a function of MyoD, we introduced 
into the E1 site of the Cdc6-wt vector a two-base mutation that 
has been previously shown to eliminate the binding of MyoD 
(Fig. 3 A; Lee et al., 2001). After transfecting this mutant vector 
(Cdc6-E1mut) either alone or together with pCMV-MyoD into 
C3H10T1/2  cells,  we  found  that  the  promoter  activity  of   
Cdc6-E1mut was now severely compromised when compared 
with that of the Cdc6-wt vector (Fig. 3 B).
Microarray analysis has established that Myf5 can reg-
ulate many of the same genes as MyoD in proliferating cells 
(Ishibashi et al., 2005). Therefore, we examined the potential 
responsiveness of the Cdc6-wt reporter to Myf5 in C3H10T1/2 
cells. After Cdc6-wt was introduced into these cells along with 
a plasmid encoding Myf5 (pCMV-Myf5), we found that the 
Figure 3.  The E1 and E2F sites are functionally 
important  to  the  activity  of  the  Cdc6  promoter.  
(A) A schematic representation of three luciferase 
(Luc)  reporter  constructs,  empty  vector  (pGL3-
basic), and a construct driven by a wild-type (wt) 
Cdc6 promoter (Cdc6-wt) or a Cdc6 promoter har-
boring mutations within the E1 site (Cdc6-mut1). 
(B) C3H10T1/2 cells were separately transfected 
with empty vector and with Cdc6-wt or Cdc6-mut1,   
either alone or with increasing amounts of a plas-
mid encoding MyoD (pCMV-MyoD). Activity is 
expressed  as  fold  increase  in  comparison  with 
activity observed with empty vector after correct-
ing for transfection efficiency (see Materials and 
methods). (C) Transcriptional-activity of the empty 
vector or the Cdc6-luciferase constructs in C2C12 
myoblasts with or without mutations within E1, E2F, 
or both sites. (B and C) Error bars represent SEM.43 MyoD activates Cdc6 in myogenic cells • Zhang et al.
satellite cells (Buckingham, 2007). As shown in Fig. 4 B, after 
the satellite cells were serum stimulated and then costained for 
Pax7 and MyoD or Pax7 and Cdc6, we found that the expres-
sion of MyoD was occurring at least 2–3 h before the expression 
of Cdc6 (Fig. 4 B). We also observed in this experiment that the   
the E2F and E1 sites nearly abolished the activity of the Cdc6 
promoter in these cells (Fig. 3 C). Overall, these experiments 
suggest that the proximal E1 site within the Cdc6 promoter   
is  responsive  to  MyoD,  and  when  considering  the  results   
presented in Fig. 2 A, it appears that both MyoD and E2F3a 
may be required to affect full transcriptional activity of the 
Cdc6 gene in muscle cells.
Expression of MyoD and Cdc6 after 
C2C12 myoblasts or primary satellite  
cells leave quiescence
Recent studies have identified several genes that are up-regulated   
as cells move out of quiescence, and of those are a class of which 
encodes proteins required for giving chromatin a “license” to   
synthesize DNA (for review see Machida et al., 2005). Cdc6 is   
one of those genes (Ren et al., 2002; Ghosh and Harter, 2003), 
and  because  our  data  indicate  that  MyoD  can  apparently   
affect its promoter (Figs. 1–3), we hypothesized that it could be 
involved in transcriptionally activating Cdc6 after satellite cells 
leave quiescence. If this were the case, by all accounts, MyoD 
ought to be expressed before Cdc6 in these cells. As an initial   
strategy  for  investigating  this  possibility,  we  induced  C2C12 
myoblasts into a state that closely mimicked the properties of 
a quiescent satellite cell. This conversion was accomplished by   
using a well-established procedure (Kitzmann et al., 1998; Spiller 
et al., 2002), which includes the use of a methionine-depleted 
DME supplemented with 1% serum (see Materials and methods). 
When low-density C2C12 myoblasts were cultured under these 
conditions for 36 h, we found that at least 95% of them were no 
longer synthesizing their DNA, as judged by the incorporation of 
BrdU (Fig. S2 A). What is more important, though, is that these 
cells were barely expressing MyoD (Fig. S2 B), as indicated by 
immunofluorescence or RT-PCR analysis. This result strongly 
indicated that the majority of the myoblasts were now in a non-
differentiated and quiescent stem cell state. We also examined   
the expression of Cdc6 in the quiescent myoblasts, and as shown 
in Fig. S2 B, its level of transcription was dramatically reduced as 
well. These data were not entirely surprising because Cdc6 was 
no longer required to prepare chromatin for DNA replication in 
these cells nor participate in checkpoint mechanisms.
Having the C2C12 myoblasts in a quiescent state enabled 
us to determine whether there were any kinetic differences in 
expression between MyoD and Cdc6 once these cells moved 
into G1. After the quiescent myoblasts were restimulated for 
growth, we found that MyoD was indeed expressed at least 2–3 h   
earlier than Cdc6, as judged by both Western blot and RT-PCR 
analysis (Fig. 4 A). In this study, the kinetics of E2F3a expres-
sion were also monitored, and the profile was found to be virtu-
ally indistinguishable from that of MyoD (Fig. S2 C). Given   
this result, it was next important to determine whether the tem-
poral expression observed between MyoD and Cdc6 was also 
essential to growth-stimulated primary satellite cells. Therefore, 
quiescent satellite cells in association with myofibers isolated 
from the muscle of an adult mouse were stimulated with serum 
and then processed for immunofluorescence using antibodies 
against Pax7, MyoD, or Cdc6. The staining for Pax7 was per-
formed in this case to mark both the quiescent and activated 
Figure 4.  MyoD is expressed before Cdc6 after C2C12 myoblasts or pri-
mary satellite cells transition from quiescence. (A) C2C12 myoblasts were 
cultured either in GM or in methionine-free medium (Met) with 1% serum 
for 36 h and then restimulated with GM for the indicated times. For Western 
blot analysis, whole cell extracts were prepared, resolved on SDS-PAGE, 
and then probed with antibodies specific to MyoD, Cdc6, and GAPDH. 
MyoD and Cdc6 mRNAs were measured by RT-PCR. GAPDH was used as 
the internal control. White lines indicate that intervening lanes have been 
spliced out. (B) Isolated extensor digitorum longus myofibers were cultured 
in basal medium (0 h) before switching to mitogen-rich medium for the acti-
vation of satellite cells. The myofibers were fixed at the indicated times and 
then coimmunostained for Pax7 (green) and MyoD (red) or Cdc6 (red). 
Immunostaining for Pax7 identifies the satellite cells (Buckingham, 2007). 
Arrows point to the individual satellite cells. Approximately 200 myofibers 
were analyzed in this experiment. Bar, 20 µm.JCB • VOLUME 188 • NUMBER 1 • 2010   44
(unpublished data). Next, lentiviral vectors expressing shRNA-64 
(shMyoD-64),  shRNA-66  (shMyoD-66),  or  the  scrambled 
shRNA (shCntrl) were separately transduced into C2C12 myo-
blasts before their conversion to quiescence, and after being 
brought to this state, they were then stimulated with serum 
(growth medium [GM]) for the indicated times (Fig. 5 A). 
Remarkably, after performing RT-PCR analysis on myoblasts 
expressing shMyoD, we observed a severe reduction not only 
in the levels of MyoD mRNA but also in the levels of Cdc6 
mRNA as well (Fig. 5 B). In contrast, quiescent myoblasts, 
which had been transduced in parallel with either empty vector   
or shCntrl, had no difficulty in expressing either one of these 
genes (Fig. 5 B). We also examined the protein levels of Cdc6 
after  the  quiescent  myoblasts  were  serum  stimulated  as  a 
function of time, and as shown in Fig. 5 C, the depletion 
of MyoD, either by shMyoD-64 or -66, resulted in the near 
absence of Cdc6 protein when compared with shCntrl. As 
expected, the protein profiles of E2F3a and Myf5 were found 
to be unaffected in the MyoD-depleted myoblasts expressing 
shMyoD-66 (Fig. S2 E and not depicted).
Next, we performed ChIP analysis on serum-stimulated 
quiescent  myoblasts  expressing  either  shMyoD-66  or  the 
scrambled shRNA to examine the occupancy of the Cdc6 
promoter under conditions of MyoD ablation. Fig. 5 D clearly 
demonstrates that both MyoD and E2F3a were recruited to the 
promoter  of  Cdc6  after  quiescent  myoblasts  expressing  the 
scrambled shRNA were stimulated with serum for 6 h. In sharp 
contrast, we were unable to detect any significant binding of 
MyoD or E2F3a to the promoter of Cdc6 after the quiescent 
myoblasts expressing shMyoD-66 were stimulated with serum 
for periods of 6, 12, or 16 h (Fig. 5 E and not depicted). This   
result implies that E2F3a may require MyoD for its recruitment 
to the Cdc6 promoter after quiescent satellite cells progress into 
the cell cycle.
activated satellite cells were coexpressing MyoD and Cdc6 by at 
least 8 h (Fig. S2 D). Notably, these results are indistinguishable 
from those observed in the growth-stimulated quiescent C2C12 
myoblasts (Fig. 4, A and B), and together with the data shown 
in Fig. 3, they strongly suggest that the expression of Cdc6 in 
newly activated satellite cells may be regulated by MyoD.
We also examined the status of Myf5 expression in both 
quiescent  and  serum-stimulated  C2C12  myoblasts.  In  con-
trast to MyoD, we found Myf5 to be highly expressed in the 
quiescent myoblasts, as determined by Western blot analysis   
(Fig. S2 C). However, after these cells reentered the cell cycle, 
its expression sharply declined, but only to resume at 8 h 
into the cell cycle (Fig. S2, C and E; and not depicted). This 
pattern of Myf5 expression as myoblasts leave quiescence has 
been previously reported by others (Kitzmann et al., 1998) and 
models, to some extent, the activity of the Myf5 locus in both 
quiescent and newly activated satellite cells (Le Grand and 
Rudnicki, 2007).
MyoD is required for the induction  
of Cdc6 after myoblasts transition  
out of quiescence
As shown in Figs. 3 and 4, our results suggested that MyoD 
participates in the activation of Cdc6 after myogenic progeni-
tors are stimulated to leave quiescence. To further investi-
gate this possibility, we used short hairpin–mediated RNAi 
(shRNA) to knock down the expression of MyoD in the hope 
of determining what effect, if any, this would have on the 
induction of Cdc6 after quiescent myoblasts were returned 
to the cell cycle. Three shRNAs (shRNA-63, -64, and -66) 
were  designed  to  specifically  target  the  coding  sequences 
of MyoD, and in the end, shRNA-64 and -66 were found to 
be the most effective in knocking down the expression of 
MyoD (85–90%) when compared with a scrambled shRNA   
Figure 5.  Knockdown of MyoD dramatically 
reduces  the  expression  of  Cdc6  in  growth-
stimulated  quiescent  myoblasts.  (A)  C2C12 
myoblasts  were  separately  transduced  with 
lentiviruses  expressing  two  distinct  shRNAs 
specific for MyoD (shMyoD-64 and -66) and 
a scramble shRNA (shCntrl). After 42 h, the 
myoblasts  were  brought  to  quiescence  and 
then stimulated to grow for the indicated times 
in GM. (B and C) After stimulation, the myo-
blasts were harvested, and the expression of 
MyoD or Cdc6 was then monitored either by 
RT-PCR (B) or by Western blotting (C). NS de-
notes a nonspecific band. EV, empty vector. 
(D and E) Cross-linked chromatin was isolated 
from  growth-stimulated  quiescent  myoblasts 
expressing a scramble shRNA (shCntrl) or an 
shRNA specific for MyoD (shMyoD-66). After-
ward, the protein–DNA fragments were immuno-
precipitated  in  parallel  with  anti-E2F3a  or 
anti-MyoD antibody (Ab) and then analyzed 
by  semiquantitative  PCR  using  primers  sur-
rounding the E1 site within the Cdc6 promoter. 
A control reaction with the use of normal rabbit 
IgG (NR IgG) is shown along with input DNA, 
which was amplified by the same set of prim-
ers. Black lines indicate that intervening lanes 
have been spliced out.45 MyoD activates Cdc6 in myogenic cells • Zhang et al.
we were unable to detect this protein at the promoter of Cdc6 
after 6 h of serum stimulation (Fig. 7 A) but did detect it after a 
period of 12 h (Fig. 7 B). Perhaps more striking is that Myf5 
can also readily associate with the Cdc6 promoter in MyoD
/ 
primary myoblasts, as demonstrated by ChIP analysis (Fig. 7 C). 
Collectively, these results suggest but do not prove that Myf5 
can act as a replacement factor for MyoD in inducing the 
promoter of Cdc6, but only under a given set of circumstances.
Discussion
In summary, the results presented in this study reveal a new 
and important role for MyoD: it can participate with other 
transcriptional factors (e.g., E2F3a) in regulating Cdc6, a gene 
which is extremely important in conferring replication compe-
tency to cells that have transitioned out of quiescence (Pelizon,   
2003). This surprising observation may be one reason why   
satellite stem cells express high levels of MyoD within hours after 
their activation and before muscle-specific gene products are 
detected (Jones et al., 2005). Indeed, our data clearly demon-
strate that when MyoD is ablated in growth-stimulated quiescent 
myoblasts, Cdc6 is not sufficiently induced, and consequently, 
these cells cannot fully progress into S phase. Thus, the ability 
of MyoD to affect full transcription from the Cdc6 promoter, 
as shown herein, is a mechanism that more than likely sets the 
stage for S phase in early activated satellite stem cells. More-
over, our discovery that MyoD can associate with the promoters 
of other genes (e.g., MCM2 and -7) that are also central to the 
regulation of DNA leads us to suspect that this activity is asso-
ciated with parallel mechanisms for promoting these cells into   
S phase. Finally, our evidence indicating that Myf5 can also 
occupy and stimulate the Cdc6 promoter is intriguing from 
the standpoint that this could reflect a failsafe mechanism for 
Entry of quiescent myoblasts into S phase 
requires MyoD
Because  Cdc6  is  such  a  key  factor  in  preparing  chroma-
tin for DNA replication in eukaryotic systems (Borlado and   
Méndez, 2008), we wanted to determine whether the deple-
tion of MyoD had any effect on the ability of growth-stimulated 
quiescent myoblasts to enter into S phase, as judged by BrdU 
incorporation. Thus, by using the strategy described in Fig. 6 A, 
we found that the percentage of MyoD-depleted myoblasts enter-
ing S phase after 16 h of serum stimulation was remarkably   
reduced  when  compared  with  myoblasts  with  the  shCntrl   
vector (Fig. 6 B). Therefore, we conclude that MyoD is required 
for inducing Cdc6 in growth-stimulated quiescent myoblasts, 
and by extrapolation, this activity could signify one mecha-
nism for preparing recently activated satellite cells to enter 
S phase.
Interestingly, although the percentage of control myo-
blasts (shCntrl) in S phase after 36 h was virtually identical to 
that  which  was  seen  after  16  h,  the  percentage  of  MyoD- 
depleted myoblasts in S phase at the 36-h time point had in-
creased at least threefold over that which was seen at the l6-h 
time point (Fig. 6 B). We propose that Cdc6 may be associated 
with this increase, only because its expression is unpredictably 
observed in the MyoD-depleted quiescent myoblasts after 16 h 
of serum stimulation (Fig. 5 C). Given that this time point 
shows no evidence for the expression of MyoD but that it does 
for Myf5 (Fig. 5 C and Fig. S2 E), we thought that Myf5 might 
perhaps be responsible for contributing to the expression of 
Cdc6 while under these conditions. Therefore, we tested this 
idea by examining the Cdc6 promoter for the occupancy of 
Myf5 in the MyoD-depleted quiescent myoblasts after serum 
stimulation. In accordance with the pattern of Myf5’s expression 
in growth-stimulated quiescent myoblasts (Fig. S2, C and E),   
Figure  6.  Depletion  of  MyoD  in  growth-stimulated 
quiescent myoblasts is associated with a reduction in 
the number of cells entering S phase. (A) C2C12 myo-
blasts were transduced with lentiviruses (shMyoD-66 
or shRNA control), and after 48 h, they were brought 
to quiescence, at which time serum (GM) was then 
added for either 16 or 36 h. (B) To monitor DNA syn-
thesis, BrdU was added to the media for 30 min at 
each of the respective times, and then immunostained, 
accordingly, for the detection of BrdU incorporation. 
The bottom panel is the quantitation of the results, and 
the bars in the histogram represent the mean percent-
ages of cells positive for BrdU per field of view. Error 
bars represent SEM. (*, P < 0.001). Bar, 20 µm.JCB • VOLUME 188 • NUMBER 1 • 2010   46
et al., 1995; Wozniak and Anderson, 2005; Parise et al., 2008). Individ-
ual myofibers were dissociated by trituration, washed, and then cultured in 
a  horse  serum  (HyClone)–coated  Petri  dish  (Kord-Valmark)  with  added 
DME to maintain the associated satellite cells in a quiescent state. To acti-
vate the associated satellite cells, the cultures were switched to DME and 
20% FBS with 0.5% chick embryo extract (Sera Laboratories International, 
Ltd) and then incubated at 37°C in 5% CO2 until harvesting. At least three 
to four mice per time point were used.
Cell culture and quiescence
C3H10T1/2 mouse fibroblasts and 293T cells were maintained in DME 
supplemented with antibiotics and 10% FBS. C2C12 skeletal muscle 
cells (provided by N. Rosenthal, European Molecular Biology Labora-
tory Monterotondo, Rome, Italy) were maintained in DME supplemented 
with 20% FBS (GM) as previously described (Mal et al., 2000, 2001). 
To prepare myotubes, myoblasts were switched to differentiating me-
dium (DM; DME, 2% heat-inactivated horse serum, and 10 µg/ml insu-
lin), and after 12 h, 10 µM cytosine arabinoside was added for 36 h 
to  eliminate  proliferating,  nondifferentiating  myoblasts  (Mal  et  al., 
2000). Methods for removing myotubes from culture dishes without qui-
escent  undifferentiated  myoblasts  were  as  previously  described 
(Kitzmann et al., 1998). In brief, trypsin at a concentration of 0.05% 
was added to cultures of myotubes followed by incubation at 37°C for 
20–30 min.
Except for minor modifications, C2C12 myoblasts were made quies-
cent as previously described (Kitzmann et al., 1998; Spiller et al., 2002). 
In brief, myoblasts were grown on tissue culture–treated polystyrene dishes 
(Corning)  and  in  medium  consisting  of  high-glucose  DME  (Invitrogen)   
supplemented  with  heat-inactivated  20%  FBS.  Upon  reaching  40–50% 
confluency, the cells were then switched after extensive washings in warm 
PBS to high-glucose DME without methionine and with 1% FBS (quiescent 
medium) for 36 or 48 h. Quiescent myoblasts, whose confluency was 
30–40%, were promoted into the cell cycle by changing the medium to 
fresh DME with 20% FBS (GM).
shRNA-mediated gene silencing
Lentiviral-based shRNA constructs (pLKO.1) expressing shRNAs targeting 
the sequences of nucleotides 1,061–1,081, 1,044–1,064, or 1,126–1,146 
of  MyoD  (GenBank/EMBL/DDBJ  accession  no.  NM_010866)  were 
purchased from Thermo Fisher Scientific and renamed shMyoD-63, -64, 
and -66, respectively. A pLKO.1 construct expressing a scrambled shRNA 
was purchased from Addgene and served as a negative control (shCntrl). 
To produce lentivirus, each of the pLKO.1 constructs was cotransfected with 
psPAX2 and pMD2G into 293T packaging cells as previously described 
(Jackson et al., 2005). Supernatants derived from these cells were then 
used to infect C2C12 myoblasts.
Promoter sequence analysis, expression plasmids, and gene reporter assays
Putative binding sites for MyoD (E-boxes) and E2F were identified along 
the 1.3-kb Cdc6 promoter by analysis with the TRANSFAC (version 7.0) 
computer software program (Matys et al., 2006). The Cdc6 promoter frag-
ment was generated by PCR from mouse genomic DNA, ligated into the   
pGL3-basic  luciferase  reporter  vector  (Promega),  and  then  sequenced   
accordingly. PCR primers (forward, 5-AGACCTGGGGCTGTCCTATT-3; 
and reverse, 5-CTGCTCAAAACTAGCCAGCA-3) were designed to amplify 
449 bp (168, +281) of the Cdc6 promoter sequence (GenBank/EMBL/
DDBJ accession no. NM_001025779), which is numbered relative to the 
transcription start site at +1, is described in the NCBI UniGene database 
(Genome View). Nucleotide substitutions were introduced into the putative 
E-box or E2F site of Cdc6-wt at position 28 (TGCAGCTGCT converted   
to  TGCAGCAACT)  or  48  (TTTGGCGC  converted  to  TTTGAAGC),   
respectively, by using a site-directed mutagenesis kit (Agilent Technologies). 
Nucleotide substitutions were also introduced into both of these sites to 
generate a double mutant. The DNA sequences of all of these constructs 
were verified accordingly.
The plasmid pCSA-MyoD expressing full-length MyoD from the CMV 
promoter  (pCSA-MyoD)  has  been  described  previously  (Skapek  et  al., 
1996),  as  have  the  CMV  promoter–driven  plasmids  pHIT3-Myf5  and 
pcDNA-mE2F3a (Wu et al., 2001; Parker et al., 2006), both of which 
were  provided  by  M.A.  Rudnicki  (Ottawa  Health  Research  Institute,   
Ottawa, Ontario K1Y 4E9, Canada) and G. Leone (The Ohio State Univer-
sity, Columbus, OH), respectively.
Luciferase assays were carried out by using the Dual-Luciferase Re-
porter Assay system (Promega) according to the manufacturer’s instruction. 
To control for transfection efficiency, all firefly luciferase values were nor-
malized to Renilla luciferase.
assuring  that  activated  satellite  cells  progress  into  S  phase 
under  conditions  of  MyoD  impairment.  This  prediction  is 
strengthened by the fact that 80% of the quiescent satellite 
cells, which are committed for myogenesis, transcriptionally 
express Myf5 (Buckingham, 2007), and exactly what function 
this provides in this context is still unclear. Therefore, a more 
general understanding of the roles of both MyoD and Myf5 
during  the  proliferative  expansion  of  adult  myogenic  stem 
cells is important from the perspective of new therapeutic ap-
proaches for neuromuscular diseases.
Materials and methods
Single myofiber isolation and culturing
Male C57BL/6 wild-type mice of 6 wk old (The Jackson Laboratory) were 
used in this study and with the approval of the Institutional Animal Care 
and Use Committee at Case Western Reserve University. The extensor digi-
torum longus muscles were removed from mice after being killed by cervi-
cal dislocation (Rosenblatt et al., 1995). To minimize satellite activation, 
muscles were digested without shaking in a dish with 1× DME plus 0.2% 
collagenase type 1 for 45 min at 35°C, as previously described (Rosenblatt   
Figure 7.  Myf5 can occupy the promoter of Cdc6 in MyoD
/ primary 
myoblasts and in MyoD-depleted quiescent myoblasts after serum stimula-
tion. (A and B) Cross-linked chromatin prepared from quiescent C2C12 
myoblasts expressing shMyoD-66 after stimulation by serum for periods 
of  6  or  12  h  was  immunoprecipitated  in  parallel  with  anti-Myf5  and 
normal rabbit IgG (NR IgG). Semiquantitative PCR was then performed 
with the use of primers surrounding the E-box site E1 within the Cdc6 
promoter. Black lines indicate that intervening lanes have been spliced out.   
(C) Crossed-linked chromatin from cultured MyoD
/ primary myoblasts 
was immunoprecipitated in parallel with anti-Myf5 or anti-MyoD antibody 
(Ab) and then analyzed by semiquantitative PCR using primers surrounding 
the E-box sites (E1 and E2) within the Cdc6 promoter. A control reaction 
with the use of normal rabbit IgG is shown along with input DNA, which 
was amplified by the same set of primers.47 MyoD activates Cdc6 in myogenic cells • Zhang et al.
using a PCR Master Mix kit (Roche) in a reaction volume of 25 µl consisting of   
3.0 µl of precipitated DNA, 10 pmol of the appropriate primers, and 0.1 µCi   
-[
32P]dCTP in buffer. The thermal cycle program for amplification of the 
Cdc6 promoter sequence was 94°C for 3 min, followed by 29 cycles 
of 94°C for 15 s, 54°C for 30 s, and then 72°C for 30 s. PCR prod-
ucts  were  resolved  on  8%  native  polyacrylamide  gels  and  visualized   
by autoradiography.
RT-PCR
Total RNA was prepared using the TRIZOL reagent (Invitrogen) accord-
ingly. cDNA was generated by using the First-Strand cDNA Synthesis kit   
(GE Healthcare), and this was then amplified by PCR using specific 
primers spanning at least two exon regions of Cdc6, MyoD, or GAPDH. 
Quantification of GAPDH levels in the same cDNA samples measured in 
separate PCR reactions served as an endogenous control. Each product 
was resolved by agarose gel electrophoresis and visualized by ethidium 
bromide staining.
Online supplemental material
Fig. S1 shows that MyoD can occupy the Mcm2 promoter in myoblasts, 
and reporter assays show that the regulatory region of Cdc6 is responsive 
to MyoD, E2F3a, or Myf5 in C3H10T1/2 cells. Fig. S2 shows the conver-
sion of C2C12 myoblasts to a quiescent state, the analysis of Myf5 and 
E2F3a expression in serum-stimulated quiescent myoblasts, the colocaliza-
tion of MyoD and Cdc6 in activated satellite cells in association with myo-
fibers, and the expression of Myf5 in quiescent myoblasts depleted of 
MyoD after serum stimulation. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200904144/DC1.
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Transfections and monitoring of DNA synthesis
For reporter gene assays, cultures of C3H10T1/2 or C2C12 myoblasts 
were transiently transfected with plasmids using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. Primary mouse 
wild-type and MyoD
/ myoblasts (provided by M.A. Rudnicki) were   
isolated and cultured as previously described (Sabourin et al., 1999).
To  monitor  for  DNA  synthesis,  a  BrdU  Labeling  and  Detection   
kit (Roche) was used. In brief, C2C12 myoblasts cultured in GM, DM, or 
quiescent medium were labeled with 10 µM BrdU for 30 min and then   
processed  according  to  the  manufacturer’s  instructions.  The  secondary   
antibody for BrdU staining was anti–mouse Alexa Fluor 568 or 488.
Antibodies, immunoblotting, and immunofluorescence
Antibodies recognizing MyoD (C-20 and M-318), Myf5 (C-20), E2F3a 
(C-20),  Cdc6  (180.2  and  H-304),  E2F4  (C-20),  E2F1  (KH95),  glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH; 6C5), and normal rabbit 
IgG were obtained from Santa Cruz Biotechnology, Inc. Hybridoma cells 
producing the anti-Pax7 mouse monoclonal antibody were provided by 
M.A. Rudnicki, and Alexa Fluor 594– or Alexa Fluor 488–conjugated goat 
anti–mouse IgG secondary antibodies for detecting primary antibodies 
were purchased from Invitrogen. The spectral compatibility for these two 
fluorophores can be seen at http://www.invitrogen.com.
Lysis of C2C12 myoblasts and conditions for immunoblot analysis 
were described previously (Mal et al., 2001). In brief, 20–40 µg of extracts 
was separated on 10% SDS-PAGE followed by transfer to polyvinylidene 
difluoride membranes, which were then probed with the primary antibody 
and, afterward, the secondary antibody followed by ECL (GE Healthcare). 
Immunofluorescence was performed on myoblasts or myotubes as previ-
ously described (Mal et al., 2000, 2001).
Myofibers were fixed at the various time points indicated in Results 
and  then  immunostained  according  to  previously  published  procedures 
(Kuang et al., 2006). In brief, fixative solution consisting of 4% paraformal-
dehyde-PBS was added to the myofibers for 10 min at RT and then washed 
with 100 mM glycine-PBS to stop the fixation. Afterward, the myofibers 
were washed three times with PBS, placed into blocking solution (0.2% 
Triton X-100–PBS with 1% BSA, 0.1% Azide, and 5% goat serum) contain-
ing the primary antibody, and then stored overnight at 4°C. After this, the 
myofibers were washed three times in PBS and then incubated with the 
appropriate secondary antibody at a dilution of 1:3,500 or 1:1,000 for 
Alexa Fluor 594 and 488, respectively.
Microscope and image capture
Fluorescence and phase-contrast images of cells or myofibers in PBS were 
acquired using an inverted microscope (DMI 4000B; Leica) with accompa-
nying dye set filters and 20× NA 0.40 or 40× NA 0.55 objectives at RT. 
Images were digitally captured using a cooled color 12-bit camera (Retiga 
2000R Fast 1394; QImaging) with QCapture Pro software (version 6.0; 
QImaging). Images were optimized for color balance, brightness, and con-
trast using Photoshop CS3 (Adobe Systems, Inc.) and then assembled into 
figures using Canvas X (ACD Systems, Inc.).
ChIP
ChIP analysis was performed as previously described (Parker et al., 2006) 
but with modifications. Primary mouse myoblasts, C2C12 myoblasts, or 
myotubes were cross-linked with 1% formaldehyde for 10 min, and after-
ward, the cells were harvested, washed with cold PBS, and resuspended in 
nuclear SDS lysis buffer containing 1% SDS, 10 mM EDTA, 50 mM Tris, pH 
8.1, and 1× Complete antiprotease cocktail (Roche). The lysate was then 
sonicated by Bioruptor (Diagenode Inc.) under conditions that consis-
tently yielded DNA fragment sizes of 100–400 bp. Sonicated chroma-
tin was clarified and then diluted 10-fold in immunoprecipitation buffer   
(16.7 mM Tris, pH 8.0, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, 
and 0.01% SDS) to bring the final concentration of SDS to 0.1%. ChIP 
reactions were performed overnight at 4°C with 50 µg chromatin and 
1–2 µg of specific antibodies. Afterward, the immunocomplexes were 
extensively washed, accordingly, and reverse cross-linked at 65°C over-
night. DNA was recovered by phenol/chloroform, ethanol precipitated, 
and then quantitated by using a fluorospectrometer (ND-3300; NanoDrop 
Technologies). The DNA precipitates and input (0.05% of total chromatin 
used for the immunoprecipitation) were analyzed by semiquantitative PCR 
using corresponding primers for the indicated promoter. The sequences 
used were Cdc6-E1 (forward, 5-TGATGAGTGACAACTAATCAG-3; and 
reverse, 5-GAGCTTTGCACTCTTCAGG-3), Cdc6-E2 (forward, 5-AGG-
TAACTGGCGATTGTGCT-3;  and  reverse,  5-GCTCTGGCTGTCTTG-
GAACT-3), and Mcm2 (forward, 5-CCTTCCGCTCTAGATTGACG-3; and 
reverse, 5-AGAGGAAGATACCGGCCAAG-3). PCR was performed by JCB • VOLUME 188 • NUMBER 1 • 2010   48
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